Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise and supplement combo tested for muscle weakness in osteoporosis

NCT ID NCT06287502

Disease control Sponsor: Kowloon Hospital, Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a 12-week program of exercise and a nutritional supplement (containing HMB, protein, vitamin D, and omega-3) could improve muscle strength and mass in people with both osteoporosis and sarcopenia (age-related muscle loss). Thirteen participants were randomly assigned to either the program or usual care. The goal was to see if grip strength, walking speed, and muscle mass could be improved.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
β-hydroxy β-methylbutyrate (HMB) nutritional supplement plus exercise training
What this could lead to
If it works, this could point toward a practical way to help older adults with osteoporosis maintain muscle strength and function.
What could go wrong
This is a very small, completed trial with only 13 participants, so results may not apply to everyone. The supplement and exercise program may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Sep 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of sarcopenia: * Low hand grip strength (Male: \<28 kg, Female: \<18 kg) AND * Low appendicular skeletal mass by bioimpedance analysis (Male: \<7.0 kg/m2 Female: \<5.7 kg/m2) 2. Diagnosed with osteoporosis by: * Fragility fracture or * T-score ≤-2.5 SDs at any site based upon BMD measurement by Dual Energy X-ray Absorptiometry (DXA) scan Exclusion Criteria: 1. Incompetent in giving consent or following commands 2. Non-ambulatory subject 3. Unstable medical conditions contributing to sarcopenia, for example but not limited to: 1. End stage organ failure 2. Unstable cardiovascular, respiratory, gastrointestinal and endocrine conditions 3. Active malignancy 4. Chronic kidney disease stage IV or above or with hyperkalaemia 5. Diabetes mellitus on medications or with unstable control 6. Terminal illness 7. Obese subjects (BMI ≥ 25.0) 8. Self-reported allergy to the ingredients of the nutrition supplement 9. Patients with metallic implants 10. Any orthopaedic pathologies affecting the strength of bilateral upper limbs 11. Any hereditary or acquired muscular diseases 12. Participation in other regular exercise programme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoporosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoporosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoporosis Sarcopenia

Contacts and locations

Locations

  • Kowloon Hospital

    Kowloon, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.